Overview

* Exact Sciences ( EXAS ) Q3 revenue grows 20% yr/yr, beating analyst expectations

* Company raises full-year 2025 revenue and adjusted EBITDA guidance midpoints

* Exact Sciences ( EXAS ) launches Cancerguard, a multi-cancer early detection test in the U.S.

Outlook

* Exact Sciences ( EXAS ) raises full-year 2025 revenue guidance to $3.220 - $3.235 bln

* Company increases full-year 2025 adjusted EBITDA guidance to $470 - $480 mln

* Exact Sciences ( EXAS ) launches Cancerguard test, potentially boosting future revenue

Result Drivers

* SCREENING REVENUE - Screening revenue increased by 22% to $666 mln, driven by Cologuard and PreventionGenetics

* PRECISION ONCOLOGY - Precision Oncology revenue grew 13% to $184 mln, supported by Oncotype DX and therapy selection tests

* CANCERGUARD LAUNCH - Launched Cancerguard, a multi-cancer early detection test, contributing to growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $850.73 $810.10

Revenue mln mln (22

Analysts

)

Q3 Net -$19.59

Income mln

Q3 Basic -$0.10

EPS

Q3 -$25.54

Income mln

From

Operatio

ns

Q3 -$17.75

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Exact Sciences Corp ( EXAS ) is $68.11, about 5% above its October 31 closing price of $64.69

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)